Biotechnology - Biotechnology, Actelion

Filter

Current filters:

BiotechnologyActelion

Popular Filters

1 to 25 of 45 results

Actelion posts strong first-quarter 2014 results

Actelion posts strong first-quarter 2014 results

17-04-2014

Switzerland’s Actelion today announced financial results for the first three months of 2014, showing…

ActelionBiotechnologyFinancial

Actelion says COMPASS-2 bosentan study fails primary endpoint

Actelion says COMPASS-2 bosentan study fails primary endpoint

17-03-2014

Europe’s largest biotech company Actelion has announced disappointing results of COMPASS-2, a Phase…

ActelionBiotechnologybosentanPfizerResearchRespiratory and PulmonarysildenafilTracleer

US Court upholds damages award in Actelion/Asahi litigation

14-03-2014

Switzerland-based Actelion says that the California Supreme Court has denied the firm’ petition for…

ActelionAsahi KaseiBiotechnologyfasudilFinancialLegalNorth AmericaRespiratory and PulmonaryUSA

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

Actelion 2013 sales and earnings beat expectations

Actelion 2013 sales and earnings beat expectations

11-02-2014

Switzerland-based Actelion, Europe’s largest biotech firm, has reported financial results for full-year…

ActelionBiotechnologyFinancial

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Tracleer “whistleblower” case by the US Department of Justice dismissed

Tracleer “whistleblower” case by the US Department of Justice dismissed

10-01-2014

In connection with a qui tam proceeding ("whistleblower case"), Swiss biotech firm Actelion previously…

ActelionBiotechnologyLegalNorth AmericaRespiratory and PulmonaryTracleerUSA

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

DMC recommends halt to Actelion’s macitentan Ph III study in digital ulcers

DMC recommends halt to Actelion’s macitentan Ph III study in digital ulcers

02-12-2013

Switzerland-based Actelion this morning announced disappointing news from an independent Data Monitoring…

ActelionBiotechnologyGastro-intestinalsmacitentanResearch

Actelion presents positive trial data for Opsumit in PAH

Actelion presents positive trial data for Opsumit in PAH

29-10-2013

Swiss biotech firm Actelion will present data on the efficacy of Opsumit from the SERAPHIN study at CHEST…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitResearch

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

US FDA gives nod to Actelion’s PAH drug Opsumit

US FDA gives nod to Actelion’s PAH drug Opsumit

21-10-2013

The US Food and Drug Administration has approved Actelion's pulmonary arterial hypertension drug Opsumit…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitRegulation

Actelion’s PAH drugs boost 4% rise in sales

Actelion’s PAH drugs boost 4% rise in sales

17-10-2013

Actelion has announced its financial results for the first nine months of 2013 revealing product sales…

ActelionBiotechnologyCardio-vascularCeptaris TherapeuticsEuropeFinancialTracleerVeletriVentavisZavesca

Actelion's Opsumit significantly reduced risk of morbidity/mortality events

29-08-2013

Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

Actelion to reinforce portfolio with acquisition

01-08-2013

Through a US subsidiary, Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech firm, has entered…

ActelionBiotechnologyCeptaris TherapeuticsMergers & AcquisitionsValchlor

Actelion posts healthy first-quarter 2013 results, forecasts double-digit growth in 2015

16-04-2013

Switzerland-based Actelion (SIX: ATLN), Europe's largest biotech firm, today (April 16) reported first-quarter…

ActelionBiotechnologyFinancial

Japanese approval for Actelion's epoprostenol "ACT"

19-02-2013

Europe's largest biotech firm Actelion (SIX: ATLN) yesterday announced that Japan's Ministry of Health,…

ActelionAsia-PacificBiotechnologyepoprostenol "ACT"RegulationRespiratory and PulmonaryVeletri

Actelion posts strong earnings growth but flat sales for 2012

14-02-2013

Switzerland-based Actelion (SIX: ATLN), Europe's largest biotechnology firm, this morning reported 2012…

ActelionBiotechnologyFinancial

Actelion's ponesimod does well in mid-stage psoriasis trial

18-12-2012

Europe's largest biotech firm Actelion (SIX: ATLN) says that its selective S1P1 modulator, ponesimod,…

ActelionBiotechnologyImmunologicalsponesimodResearch

Actelion filing for EU approval of Opsumit accepted

23-11-2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

1 to 25 of 45 results

Back to top